AstraZeneca Highlights Cancer Drug Data at ESMO Congress

AstraZeneca used the European Society for Medical Oncology (ESMO) congress in Madrid, Spain, to showcase findings from its cancer drug portfolio, presenting research on established treatments and experimental medicines. The company's presentations highlighted potential new drug combinations and a targeted chemotherapy candidate that could broaden its oncology offerings.

According to STAT, four of the 12 presentations scheduled for the congress's presidential sessions featured AstraZeneca medicines. The research covered a range of oncology programs, including combinations of already approved drugs and newer compounds under development.

The presentations demonstrated the scope of AstraZeneca's cancer research, as the pharmaceutical company builds on the performance of its existing oncology medicines while investigating additional treatment options.

Susan Galbraith, head of cancer research and development at AstraZeneca, said the presentations reflected both the breadth of the company's drug portfolio and the quality of its supporting evidence.

"That does speak to the breadth of the portfolio, but also the depth and quality of the data that we're presenting," said Susan Galbraith, head of cancer research and development at AstraZeneca.

The congress provided a platform for the company to present findings from medicines at different stages of development. Its research included combinations involving approved drugs and a potential targeted chemotherapy that could eventually reach the market.

The findings were presented at the European Society for Medical Oncology's annual congress in Madrid, where AstraZeneca's contributions featured prominently among the presidential sessions, according to STAT's coverage of the meeting.